1. Mean change from baseline in disease and disability outcomes at 6 months for abatacept initiators by anti-CCP status.
Mean change from baseline in disease and disability outcomes at 6 months for abatacept initiators by anti-CCP status. Model adjusted by baseline age, sex, body mass index, CDAI score, comorbidity index, and number of prior biological DMARD. *** p ≤ Anti-CCP status was defined as either anti-CCP–positive (≥ 20 units/ml) or anti-CCP–negative (< 20 units/ml). Patient numbers: unadjusted anti-CCP+, n = 362; unadjusted anti-CCP−, n = 204; adjusted anti-CCP+, n = 361; adjusted anti-CCP−, n = 203. Anti-CCP: anticyclic citrullinated peptide antibodies; CDAI: Clinical Disease Activity Index; DMARD: disease-modifying antirheumatic drug.
Leslie R. Harrold et al. J Rheumatol 2018;45:32-39
©2018 by The Journal of Rheumatology